Nishikawa, Hiroyoshi

Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota

Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature

Gut microbiota and healthT-cell and B-cell Immunology

Cited by 2,872

Regulatory T cells in tumor immunity

Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 944

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 892

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).

Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 890

Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers

Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 871

Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

Kakihana, K., Fujioka, Y., Suda, W., Najima, Y., Kuwata, G., Sasajima, S., Mimura, I., Morita, H., Sugiyama, D., Nishikawa, H., et al. (2016) · Blood

Hematopoietic Stem Cell TransplantationGut microbiota and health

Cited by 367

Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody

Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 205

Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids

Tokunaga, A., Sugiyama, D., Maeda, Y., Warner, A. B., Panageas, K. S., Ito, S., Togashi, Y., Sakai, C., Wolchok, J. D., & Nishikawa, H. (2019) · Journal of Experimental Medicine

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 124

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., et al. (2020) · Journal of Experimental Medicine

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 96

Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP trial)

Kawazoe, A., Kuboki, Y., Shinozaki, E., Hara, H., Nishina, T., Komatsu, Y., Yuki, S., Wakabayashi, M., Nomura, S., Sato, A., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 93